Angiotensin II formulations and their impact on reproducibility, reduction and refinement (3R) of the animal models of hypertension.

30 April 2022 (08:30 - 17:00)

Organised by:

About the speaker

Doctor Ryszard Nosalski

Queen's Medical Research Institute, Edinburgh (United Kingdom of Great Britain & Northern Ireland)

4 More presentations in this session

Presentation thumbnail

Beta-catenin C-terminus signaling promotes neointimal formation after vascular injury by inducing the sphingosine-1 phosphate receptor-1 expression

Doctor G. Oliveira-Paula (Abilene, US)

Presentation thumbnail

Mapping the low-density lipoprotein interactome in mouse atherosclerosis

Mrs R. Muniz (Madrid, ES)

Presentation thumbnail

Tissue engineered vascular patch fabrication using hybrid 3D printing and electrospinning

Doctor E. Bevilacqua (Seville, ES)

Presentation thumbnail

Ranolazine induced modulation of intracellular Na+ concentration impacts inflammatory response and reduces atherosclerotic plaque progression

Doctor M. Lenz (Vienna, AT)

Access the full session

Session thumbnail

Late-Breaking Science - Poster session 2

The Event

Event poster

Frontiers in CardioVascular Biomedicine 2022

30 April 2022 08:30 CET

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources